Anti-fgfr2 Monoclonal Antibody Fpa144 Uses, Dosage, Side Effects and more
Anti-fgfr2 Monoclonal Antibody Fpa144 is under investigation in clinical trial NCT03694522 (A Study of Anti-fgfr2 Monoclonal Antibody Fpa144 (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
| Trade Name | Anti-fgfr2 Monoclonal Antibody Fpa144 |
| Generic | Bemarituzumab |
| Bemarituzumab Other Names | Anti-fgfr2 monoclonal antibody fpa144, Bemarituzumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
